Jun142015

European Hematology Association Congress 2015

The European Hematology Association's 20th Annual Congress was June 11 - 14, 2015 in Vienna. The Congress provided a forum for presenting original unpublished data and sharing ideas for hematological innovation as well as disseminating evidence-based knowledge of primary clinical relevance. Congress attendees included hematologists and affiliated professionals.

Those attending this year's EHA Congress were able to:

  • Enhance their knowledge of evidence-based approaches on diagnosis and treatment for hematologic diseases.
  • Access the latest results on clinical and translational research in hematologic disorders.
  • Be updated on emerging innovative techniques, diagnostic tools and risk-assessment strategies in hematology and its subspecialties.
  • Communicate, collaborate and network with representatives of a large international audience – medical professionals, national hematology societies, patient groups, medical industry and the media.
Highlights from the EHA Congress are provided by Fuse Health.

 

Congress Highlights 

TYK2 PATHWAY

Late breaking poster garnering attention at EHA 2015

THE TYK2 PATHWAY AS A NOVEL THERAPEUTIC INTERVENTION SITE IN AGGRESSIVE T-CELL LYMPHOMA

 

 

prIME Oncology in Relapsed Refractory Multiple Myeloma

A well done symposium by prIME Oncology in Relapsed Refractory Multiple Myeloma: Embracing the Person in Personalized Care - incorporating patient Yelak Beru as one of the speakers, sharing his perspective along every step of the clinical presentation.  It raised the bar on patient advocacy on an International level.  One of Yelak's takeaways for the physicians, "educate us patients through social media. We appreciate having information channeled to us."  Yelak may have convinced Dr. Palumbo to start tweeting. 

 

PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB

Canadians at EHA.

Laurie Sehn (Centre for Lymphoid Cancer BCCA) sharing results of late breaker abstract GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA  

the real life analysis from the The CML patient registry

REAL LIFE ANALYSIS OF CML MANAGEMENT DEMONSTRATES THAT SECOND-LINE THERAPY IS FREQUENTLY USED BUT IS PREMATURELY DISCONTINUED FOR INTOLERANCE: REPORT  OF THE GROUPE QUÉBÉCOIS DE RECHERCHE EN LMC-NMP

Lambert Busque (Haematologist, Maisonneuve-Rosemont, Quebec) discussing the conclusions of the real life analysis from the The CML patient registry of CML-MPN Quebec Research Group (www.gqr-lmc-nmp.ca).

Visit the EHA Learning Centre online to get more information about congress presentations and abstracts.

Idelalisib plus ofatumumab in CLL

Positive phase 3 trial data. 

 

 

 

 

 

frail patients with DLBCLNew options for elderly, frail patients with DLBCL

idelalisib + rituximab in CLL Quality of life benefits with idelalisib + rituximab in CLL



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Like with Social Media